Last reviewed · How we verify
NCT05759221: Sopranos
Peripheral Airway Biopsy in Sarcoidosis
NA trial testing Bronchoscopy with airway biopsy in Sarcoidosis, Pulmonary in 79 participants. Completed in 31 March 2024.
31 December 2023
Quick facts
| Lead sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 79 |
| Start date | 20 October 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 March 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Bronchoscopy with airway biopsy
Conditions studied
- Sarcoidosis, Pulmonary — all drugs for Sarcoidosis, Pulmonary →
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Who can join
18 and older, any sex, with Sarcoidosis, Pulmonary. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Airway involvement in sarcoidosis was demonstrated in a meaningful, albeit variable, proportion of patients through biopsy of the central, endoscopically visible airways. Ideally, biopsy of peripheral airways, nowadays possible with the introduction in the market of ultrathin bronchoscopes, might be associated with an increased diagnostic yield for the detection of granulomas.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05759221
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sarcoidosis, Pulmonary
Currently open trials in the same condition.
- NCT05841758 — Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis · Phase 4 · recruiting
- NCT06479603 — RCT of Nintedanib in Fibrotic Sarcoidosis · Phase 4 · recruiting
- NCT05746039 — Feasibility of Semaglutide in Advanced Lung Disease · Phase 1, PHASE2 · recruiting
- NCT05291468 — the PHENOSAR Trial: Use of Antibiotics in Treatment of Sarcoidosis · NA · active not recruiting
- NCT05567133 — Risk Indicators of Sarcoidosis Evolution-Unified Protocol · recruiting
Other Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials
Trials by the same sponsor.
- NCT07514572 — Impact of Estimated Weight and Height on Nutritional Assessment in Elderly · NA · not yet recruiting
- NCT07504679 — Adipose Visceral and Epicardial Risk Evaluation · NA · not yet recruiting
- NCT07520643 — MISTIC Study: Atherosclerosis, Neurocognition & Cardiovascular Signaling · not yet recruiting
- NCT07479238 — Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy · not yet recruiting
- NCT07494227 — Development of the SC-IBD Self-Care Measurement Scale · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05759221 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Last refreshed: 5 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05759221.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing